Analysts expect Acurx Pharmaceuticals, Inc. to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 |
Analysts expect Acurx Pharmaceuticals, Inc. to report earnings per share of -0.40 for Q3 26, against a range of -0.42 to -0.38. The most recent reported quarter, Q2 26, came in at -0.53, a 32.5% miss against the -0.40 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.40 | -3.20 | -2.20 | -1.89 | -1.23 | -0.73 | -0.62 | -0.53 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -2.60 | -3.08 | -2.50 | -2.07 | -1.27 | -1.00 | -1.18 | -0.38 | -0.38 | -0.34 | -0.39 | -0.38 | 0.11 | 0.27 | -0.56 | -0.77 | ||||||||||
| Low Estimate | -3.06 | -3.44 | -3.04 | -2.49 | -1.47 | -1.14 | -1.32 | -0.42 | -0.42 | -0.40 | -0.43 | -0.44 | 0.09 | 0.23 | -0.62 | -0.85 | ||||||||||
| Consensus Estimate | -2.83 | -3.26 | -2.77 | -2.28 | -1.37 | -1.07 | -1.25 | -0.40 | -0.40 | -0.37 | -0.41 | -0.41 | 0.10 | 0.25 | -0.59 | -0.81 |